Abagovomab: An anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer Journal Article
| Authors: | Grisham, R. N.; Berek, J.; Pfisterer, J.; Sabbatini, P. |
| Article Title: | Abagovomab: An anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer |
| Abstract: | Ovarian cancer remains the leading cause of death due to gynecologic malignancies. Most patients present with advanced disease at the time of diagnosis. Although many have a good initial response to surgical debulking and platinum-based chemotherapy, relapse is common, with the eventual development of chemotherapy resistance. Innovative treatments are needed in the remission setting to prolong the disease-free interval or prevent recurrence. Abagovomab is a murine monoclonal anti-idiotypic antibody (molecular wieght: 165-175 kDa) that functionally imitates the tumor-associated antigen, CA-125. It has been shown to be well tolerated and to induce a sustained immune response in initial Phase I and II clinical trials. An ongoing, double-blind, placebo-controlled, multicenter, Phase III trial (MIMOSA) completed its double-blind period in December 2010 and will compare abagovomab maintenance therapy to placebo, which will definitively determine the efficacy of this immunotherapeutic approach in patients with ovarian cancer. © 2011 Future Medicine Ltd. |
| Keywords: | cancer survival; protein expression; unclassified drug; drug tolerability; fatigue; placebo; drug efficacy; drug safety; nonhuman; ovarian cancer; ovary cancer; anemia; leukopenia; nausea; vomiting; myalgia; abdominal pain; chill; fever; injection site reaction; immune response; immunotherapy; cytotoxic t lymphocyte; headache; ca 125 antigen; ca-125; drug binding; vaccine; mucin; phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); protein muc 16; drug marketing; multicenter study (topic); abagovomab; anti-idiotype; controlled clinical trial (topic) |
| Journal Title: | Immunotherapy |
| Volume: | 3 |
| Issue: | 2 |
| ISSN: | 1750-743X |
| Publisher: | Future Medicine |
| Date Published: | 2011-02-01 |
| Start Page: | 153 |
| End Page: | 162 |
| Language: | English |
| DOI: | 10.2217/imt.10.100 |
| PROVIDER: | scopus |
| PMCID: | PMC3221001 |
| PUBMED: | 21322756 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 23 June 2011" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work